The Symphion is an alternative to power morcellation procedures, which have come under increased scrutiny over concerns that they can inadvertently spread undetected cancer cells. The company plans to unveil the system at the American Assn. of Laparoscopists annual meeting in Vancouver Nov. 17-21.
"The Symphion system limits the amount of fluid that can be absorbed by the patient and provides excellent visualization with internal pressure monitoring and spot coagulation," Dr. Amy Garcia of Albuquerque’s Center for Women’s Surgery said in a statement. "These features, coupled with bipolar resection, are game changers that greatly benefit both the clinician and the patient."
Boston Scientific acquired Symphion through its recent takeover of IoGyn, saying at the time that it plans to pair Symphion with its Genesys HTA System for abnormal uterine bleeding “to create a compelling set of gynecologic surgery products.”